[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Circassia Group Plc LSE:CIR London Ordinary Share GB00BJVD3B28 ORD 0.08P
  Price Change % Change Share Price Shares Traded Last Trade
  0.40 1.07% 37.65 4,937,169 16:35:12
Bid Price Offer Price High Price Low Price Open Price
37.75 38.15 38.50 36.40 38.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 23.90 -18.40 -9.00 157
Last Trade Time Trade Type Trade Size Trade Price Currency
17:38:58 O 69 37.65 GBX

Circassia (CIR) Latest News (5)

More Circassia News
Circassia Investors    Circassia Takeover Rumours

Circassia (CIR) Discussions and Chat

Circassia Forums and Chat

Date Time Title Posts
17/9/202107:30Circassia Pharma - Focussed on respiratory disease1,023
16/9/202110:49Circassia Pharma PLC 1,225
27/1/202016:20money wanted-
13/12/201908:24Capricorn Resouces PLC - 50% premium in half a day814
10/2/200515:35100 % on no time12

Add a New Thread

Circassia (CIR) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-09-17 16:42:2437.656925.98O
2021-09-17 16:05:4037.6550,00018,825.00O
2021-09-17 15:35:1237.654,4731,684.08UT
2021-09-17 15:29:4738.0016964.22AT
2021-09-17 15:29:2638.007729.26AT
View all Circassia trades in real-time

Circassia (CIR) Top Chat Posts

DateSubject
18/9/2021
09:20
Circassia Daily Update: Circassia Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker CIR. The last closing price for Circassia was 37.25p.
Circassia Group Plc has a 4 week average price of 36.25p and a 12 week average price of 27.90p.
The 1 year high share price is 42p while the 1 year low share price is currently 19.86p.
There are currently 417,661,192 shares in issue and the average daily traded volume is 2,228,142 shares. The market capitalisation of Circassia Group Plc is £157,249,438.79.
16/9/2021
09:16
andyview: A little surprised with todays price action.. gla
16/9/2021
07:08
ayl30: Good results rns and materially ahead forecast, must be good for the share price
06/8/2021
13:58
thelongandtheshortandthetall: Haha. I'll be excited when CIR is 62p - Namely when the new directors get their bonuses.
13/7/2021
07:04
pro_s2009: Update out: https://www.londonstockexchange.com/news-article/CIR/first-half-trading-update/15055803 ,
22/6/2021
10:51
thelongandtheshortandthetall: From what I can tell, CIR have 70% more units sold than in 2019 - where they would have broken even on today's reduced cost base. The resultant consumable sales should be going at quite a clip. So with that in mind I'm almost certain they have gone beyond brake even and the recent notification of £11.2m in cash makes the need for additional pennies incredibly unlikely IMO
09/5/2021
09:36
1pencil: Well aware of the shares being issued, just hadn't linked the two given the discrepancy between dates. On the 30th April CIR issued a TR1 in respect of options being exercised, this also gave total voting rights or shares for calculation purposes, perhaps this triggered their decision to put out a TR1? From the fund raise RNS shares were admitted to AIM on 27th March "Application for Admission Application has been made to the London Stock Exchange for the Subscription Shares to be admitted to trading on AIM. Admission of and dealings in the Subscription Shares is expected to commence at 8.00 a.m. on 25 March 2021. Following Admission, the Company will have 417,661,192 Ordinary Shares of 0.08p in issue, each carrying one voting right. No shares are held in treasury."
08/5/2021
23:52
marketgem: You seem to be able to research so I'm a little suspicious of your agenda. It's not difficult to see there was shares issued on the 30/4 same as when the threshold was cross. Circassia Group Plc - Total Voting Rights #CIR https://www.voxmarkets.co.uk/rns/announcement/2a0e0a89-eeb5-4a6c-b187-1b2f9df00589 #voxmarkets undefined
21/4/2021
15:29
1pencil: On the topic of why would Astra Zeneca dispose of their holding. My reading of the situation is it formed part of the original partnership agreement back in 2017 (see below excerpt). Therefore it seems reasonable to assume AZ will at some point unwind this position now the partnership has ended. "Under the terms of the agreement, AstraZeneca will receive $50 million in Ordinary Shares in Circassia, calculated by reference to the lower of the weighted average share price of Circassia over the period 20 days (i) prior to signing or (ii) prior to closing (subject to a maximum number of shares). Circassia will also pay $100 million at the earlier of approval of Duaklir in the US or 30 June 2019. Should Circassia decide to exercise the option to sub-license the commercial rights to Tudorza in the US, Circassia will pay up to a further $80 million." HTTPS://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-and-circassia-enter-strategic-collaboration-in-respiratory-disease-17032017.html#
09/4/2020
07:06
pro_s2009: Proposed transfer of assets to and termination of agreement with AstraZeneca for consideration to be set off against debt and accrued interest Oxford, UK - 9 April 2020 Circassia Pharmaceuticals plc, ("Circassia" or "the Company"; LSE: CIR) announces that the Board has concluded that it is in the best interests of the Company to terminate the development and commercialisation agreement between the Company and AstraZeneca UK Limited, a subsidiary of AstraZeneca plc (LSE/STO/NYSE: AZN) (AstraZeneca) for the U.S. commercial rights to Tudorza(R) and Duaklir(R) and transfer the assets to AstraZeneca (the Transaction). On completion of the Transaction, AstraZeneca will acquire the U.S. commercial rights to Tudorza(R) and Duaklir(R) together with certain ancillary rights and assets, from Circassia the consideration for which shall be equal to, and shall be satisfied by way of set-off against, the entirety of the loan amount outstanding from the Company to AstraZeneca, together with accrued interest owed by the Company to AstraZeneca, as at the date of completion of the Transaction (being approximately US$149.9 million as at the date of announcement) AstraZeneca will retain its 18.9% shareholding in the Company. Subject to receipt of necessary approvals, it is anticipated that the Transaction will complete in no longer than three months. The proposed Transaction will constitute a fundamental change of business of Circassia under Rule 15 of the AIM Rules for Companies and is therefore conditional on, inter alia, the passing of an ordinary resolution to approve the Transaction at the General Meeting, a circular convening the General Meeting is expected to be posted to Shareholders shortly. In addition, the Transaction is considered to constitute a related party transaction under Rule 13 of the AIM Rules for Companies. On completion of the Transaction, Circassia proposes to change its name to Circassia Group plc, subject to the passing of a special resolution to approve the Company's change of name at the General Meeting. Ian Johnson, Circassia's Executive Chairman, said: "As a Board and Management team, we conducted a strategic review of our business and its prospects, concluding that it would be in the best interests of both patients and our shareholders for us to terminate the development and commercialisation agreement between the Company and AstraZeneca UK Limited for the U.S. commercial rights to Tudorza(R) and Duaklir(R). As we look to move forwards with a primary focus on our Niox(R) respiratory diagnostic platform, we are confident in our ability to drive long-term growth. Upon completion, this transaction will transform Circassia into a debt-free business with a strong revenue-generating business, with which we have the potential to expand into new territories and a commercial infrastructure that can in the medium term be further leveraged through broadening its range of products. This fundamental change in the business will place us in a strong position to deliver improved shareholder value."
17/1/2020
09:45
x54v: Richard Griffiths obviously hugely keen here building up a seriously large 28.61% position in recent months Https://investegate.co.uk/circassia-pharma-plc--cir-/rns/holding-s--in-company/201907021756072649E (<3% -> 3.33%) Https://investegate.co.uk/circassia-pharma-plc--cir-/rns/holding-s--in-company/201907051207426686E (3.33% - 7.31%) Https://investegate.co.uk/circassia-pharma-plc--cir-/rns/holding-s--in-company/201907221612213259G (7.31% - 8.76%) Https://investegate.co.uk/circassia-pharma-plc--cir-/rns/holding-s--in-company/201909171201406241M (8.76% - 25.17%) Https://investegate.co.uk/circassia-pharma-plc--cir-/rns/holding-s--in-company/201911261803047617U (25.17% - 27.29%) Https://investegate.co.uk/circassia-pharma-plc--cir-/rns/holding-s--in-company/202001031153257197Y (27.29% - 28.61%)
Circassia share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
CIR
Circassia
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210918 11:50:39